Finance
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
C
CNBC
April 27, 2026·1 min read
GM
FinanceIntellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.
Original article
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Published by CNBC